-- Robert Preidt
THURSDAY, May 10 (HealthDay News) -- A new weight-loss drug that
is awaiting approval from the U.S. Food and Drug Administration
showed promising results in a recent international trial,
Volunteers who took Qnexa, a combination of the drugs
phentermine and topiramate, experienced substantial weight loss,
even if they had many weight-related health problems, the study
found. The findings were reported this week during the European
Congress on Obesity in Lyon, France.
The 56-week clinical trial included 994 patients who took a
placebo, 498 who took a medium dose of Qnexa, and 995 who took a
high dose of the drug.
Patients who took Qnexa had significantly greater weight loss
than those who took the placebo, researchers Stephan Rossner, of
the Karolinska Institute in Stockholm, Sweden, and Arya Sharma, of
the University of Alberta in Edmonton, Canada, said in a news
release from the European Congress on Obesity.
Earlier this year, a U.S. Food and Drug Administration advisory
panel recommended that the agency approve the drug for the
treatment of obesity. The FDA is scheduled to announce its decision
July 17. European officials are expected to make a decision about
the combination treatment by mid-summer.
Meanwhile, an FDA advisory panel on Thursday gave its blessing
to yet another new weight-loss drug, locaserin, despite lingering
concerns about possible cardiac side effects, the
Associated Press reported.
Although effective at reducing weight, Qnexa, manufactured by
Vivus Inc., was denied approval in 2010 because of its potential
side effects. Before making its decision in February, the FDA
advisory panel reviewed two years of data on the drug; when
advisers previously voted on Qnexa, only one year's worth of
follow-up data was available.
Qnexa combines the appetite suppressant phentermine (brand name
Adipex-P) and the anti-seizure/migraine medication topiramate
(brand name Topamax). Phentermine once was prescribed widely as the
"phen" part of the fen-phen weight-loss drug, which was withdrawn
from the market in 1997 after its use was linked to both high blood
pressure in the lungs and heart valve disease. The problems were
related to the "fen," or fenfluramine, part of the combination, not
the phentermine, scientists said.
No new weight-loss drug has been approved in the United States
in the past 13 years, according to published reports. As it stands,
Xenical is the only FDA-approved drug specifically for long-term
use -- up to a year -- for weight loss. Xenical is sold over the
counter as Alli. Other drugs, however, may be used off-label to
promote weight loss.
Last April, a study funded by Vivus found that obese patients
taking Qnexa lost an average of 22 pounds over a year, while also
lowering their blood pressure and cholesterol levels.
Dr. Louis Aronne, founder and director of the Comprehensive
Weight Control Program at New York-Presbyterian Hospital/Weill
Cornell Medical Center in New York City, was cautiously optimistic
that Vivus did a good job responding to FDA safety concerns, and
that the FDA will give the drug its nod of approval -- with some
caveats. Aronne was not involved in the trials but has been an
adviser to Vivus and other companies developing weight-loss
Vivus has reported that Qnexa may increase the risk of cleft lip
in babies of women who use the drug while pregnant. Aronne said the
birth defect concern could be addressed through education on who
should and should not use the drug.
"We have learned our lessons with weight-loss drugs," he said. "They need to be used in the right people under the right circumstances." The heart risks need to be weighed against reductions in heart disease risk factors that come with weight loss, he explained.
Qnexa is no riskier than bariatric surgery, Aronne said, but it
can be distributed more widely. He hopes for a compromise that
allows the new compound to be prescribed but not misused.
"Once new medications are approved, local medical boards will need to enforce rules and make sure these medications are prescribed appropriately to the right candidates," he said. "We don't want to open up pill mills."
Dr. Scott Kahan, an obesity expert at Johns Hopkins University
in Baltimore and director of the National Center for Weight and
Wellness in Washington, D.C., agreed that Qnexa looks
"The weight-loss effects are striking and approaching the amount of weight loss over two years that we get with bariatric surgery," Kahan said. "This is really impressive."
Learn more about weight-loss medications at the
U.S. National Institutes of Health.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.